MODIFIED PTO/SB/08 A & B (06-03) Complete if Known Substitute for Form 1449 A & B/PTO JAN 2 6 2008 INFORMATION DISCLOSURE STATEMENT BY APPLICAN TO TRADES! Application Number 10/551,764 Sonfirmation Number Unknown Filing Date October 03, 2005 First Named Inventor Young Min KIM (use as many sheets as necessary) Art Unit Unassigned **Examiner Name** Unassigned Sheet of 1 Attorney Docket Number Q90374

			U.S. 1	PATENT DOCUME	ENTS
Examiner Initials*	Cite	Document	Number		
	No.1	Number	Kind Code ¹ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US			
		US			
		US		·	
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Familian Data A Day			Publication Date	Name of Botton	T	
Initials*	No.'	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶	
		ļI						
		 						
								
l				L				

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS				
Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.				
		Brian C. Cunningham et al., "Rational design of receptor-specific variants of human growth hormone", Proc. Natl. Acad. Sci. USA, Vol. 88, April 1991, pp. 3407-3411				
		Dieter Haffner et al., "Metabolic Clearance of Recombinant Human Growth Hormone in Health and Chronic Renal Failure", J. Clin. Invest., Vol. 93, March 1994, pp. 1163-1171				
		Ross Clark et al., "Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol", The Journal of Biological Chemistry, Vol. 271, No. 36, Sept. 6, 1996, pp. 21969-21977				
		Yoshinobu Fukumori et al., "Coating of Pharmaceutical Powders by Fluidized Bed Process. III. Aqueous Coating with Ethyl Acrylate-Methyl Methacrylate-2-Hydroxy-ethyl Methacrylate Copolymer and the Dissolution Properties of the Products", Chem. Pharm. Bull., Vol. 36, 1988, pp. 3070-3078				
		Steven M. Chamow et al., "Modification of CD4 Immunoadeshin with Monometh-oxypoly(ethylene glycol) Aldehyde via Reductive Alkylation", Bioconjugate Chem., Vol. 5, 1994, pp. 133-140				
		Liew-Cheng The & George E. Chapman, "Determination of the Effect of Acetylation of Specific Lysine Residues in Human Growth Hormone on its Affinity for Somatogenic Receptors by an Affinity Selection Technique", Biochemical and Biophysyical Research Communications, Vol. 150, No. 1, January 15, 1988, pp. 391-398				
		A. L. Baldwin et al., "Bioactivity and immunoactivity of growth hormone during dynamic testing of patients with acromegaly", Acta Endocrinologica (Copenh), Vol. 119, 1988, pp. 326-332				
		M. Bozzola et al., "Evaluation of growth hormone bioactivity using the Nb ₂ cell bioassay in children with growth disorders", J. Endocrinol. Invest., Vol. 21, 1998, pp. 765-770				
$V \perp$		James A. Wells et al., "The Molecular Basis for Growth Hormone-Receptor Interactions", Recent Progress in Hormone Research, Vol. 48, 1993, pp. 253-275				

Examiner Signature	/Ronald Niebauer/	Date Considered	05/08/2007	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

JC05 Rec'd PCT/PTO 03 OCT 2005 MODIFIED PTO/SB08 A & B (08-03)

Substitute for Form 14	40 A & B/DTO			Complete if Known			
Substitute for Portifi 14	49 A & B/FIU			Application Number	Unassigned		
INFO	RMATION D	DISCLOS	HIRE	Confirmation Number	Udkany RE4 7/1		
	EMENT BY			Filing Date	U460 0 551 764		
<u> 51A1</u>	EMENI DI	AFFLIC	ANI	First Named Inventor	Young Min KIM		
(use	e as many sheets	as necessa	<i>(או</i>	Art Unit	Unassigned		
			i	Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	Q90374		

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite	Document	Number	Dublination Date				
	No.1	Number	Kind Code ^I (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			
/RN/		US 6,106,828		08-22-2000	Novo Nordisk A/S			
/RN/	Jene 244.	US 4,179,337		12-18-1979	Frank F. Davis et al.			
7144		US						
		US						
		US	,					
		US						
		US						
		US						
		US						

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document			Publication Date	Name of Patentee or			
Initials*	No.'	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶		
		ļ							
		 							
	- :								
	•								
		 							
		 		1					
				1			· · · · · · · · ·		
			ı						

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. I	The state of the detail (in detail the detail and the article (when appropriate) the or the item (book, inagabite,						
/RN/		Kang Choon Lee et al., "Isolation, Characterization, and Stability of Positional Isomers of Mono- PEGylated Salmon Calcitonins", <i>Pharmaceutical Research</i> , Vol. 16, No. 6, 1999, pp. 813-818						
/RN/		Ya-Ping Lee et al., "PEGylated Recombinant Human Tumor Necrosis Factor Alpha: Phamacokinetics and Anti-tumor effects", <i>Biological and Pharmaceutical Bulletin</i> , Vol. 24, No. 6, 2001, pp. 666-670						
			 					

l .	Donald Nichauarl	L	05/08/2007
Evaminar Signatura	/Ronald Niebauer/		L U5/U8/ZOU/ F
Examiner Signature		Date Considered	00/00/2001

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.